Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23576541 | 0.88 | — | — | |
| SCHEMBL15823364 | 0.77 | EPHX1 (0.37) | CES2CES1SMN1; SMN2EPHX1NPC1 | |
| SCHEMBL2906286 | 0.77 | CYP19A1 (0.32) | CES2CES1EPHX1 | |
| SCHEMBL2908887 | 0.77 | TSHR (0.36) | CES2CES1ALDH1A1TSHREPHX1 | |
| SCHEMBL2907813 | 0.77 | NAAA (0.36) | HSD11B1ALDH1A1EPHX1NPSR1EPHX2 | |
| SCHEMBL1186624 | 0.76 | — | — | |
| SCHEMBL312980 | 0.76 | CES2 (0.42) | CES2CES1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL9852667 | 0.76 | TSHR (0.34) | ALDH1A1TSHRSMN1; SMN2NPSR1EPHX2 | |
| SCHEMBL697219 | 0.74 | NAAA (0.34) | HSD11B1ALDH1A1EPHX1EPHX2 | |
| SCHEMBL698468 | 0.74 | ALDH1A1 (0.43) | ALDH1A1TSHRNPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101868460-A | 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivative or its salt, process for the preparation thereof and pharmaceutical composition comprising the same | KUKJE PHARM IND CO LTD | 2010-10-20 | — | — | CN | claimed |
| CN-102123588-B | Substituted imidazole combinations | PFIZER | 2013-10-23 | — | — | CN | disclosed |
| CN-101594861-B | Modulation of prostaglandin/cyclooxygenase metabolic pathways | HUNTER FLEMING LTD GB | 2013-06-12 | — | — | CN | disclosed |
| CN-101166534-B | Therapeutic agent for chronic obstructive pulmonary disease | DAINIPPON SUMITOMO PHARMA CO | 2011-09-21 | — | — | CN | disclosed |
| CN-102123588-A | Substituted imidazole combinations | PFIZER | 2011-07-13 | — | — | CN | disclosed |
| CN-101868460-A | 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivative or its salt, process for the preparation thereof and pharmaceutical composition comprising the same | KUKJE PHARM IND CO LTD | 2010-10-20 | — | — | CN | disclosed |
| EP-2217564-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| CN-101594861-A | The adjusting of prostaglandin/cyclooxygenase metabolic pathways | HUNTER FLEMING LTD (GB) | 2009-12-02 | — | — | CN | disclosed |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009033054-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| CN-101151031-A | Tricyclic cytoprotective compounds | HUNTER FLEMING LTD (GB) | 2008-03-26 | — | — | CN | disclosed |
| CN-1330652-C | Novel carbapenem compounds | SUMITOMO PHARMA (JP) | 2007-08-08 | — | — | CN | disclosed |
| CN-1247582-C | Novel carbapenem compounds | DAINIPPON SUMITOMO PHARMACEUTI (JP) | 2006-03-29 | — | — | CN | disclosed |
| CN-1612879-A | Novel carbapenem compounds | SUMITOMO PHARMA (JP) | 2005-05-04 | — | — | CN | disclosed |
| CN-1489589-A | Novel carbapenem compounds | ס����ҩ��ʽ���� | 2004-04-14 | — | — | CN | disclosed |
| CN-1065532-C | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO CO (JP) | 2001-05-09 | — | — | CN | disclosed |
| EP-0580429-B1 | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence | LILLY CO ELI (US) | 1997-01-22 | — | — | EP | disclosed |
| CN-1132750-A | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO CO (JP) | 1996-10-09 | — | — | CN | disclosed |
| EP-0580429-A1 | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence | ELI LILLY AND COMPANY (US) | 1994-01-26 | — | — | EP | disclosed |
| US-5192751-A | Administering a decahydroisoquinoline derivative | ELI LILLY AND COMPANY (US) | 1993-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | CES2 537/4885CES1 1564/4885HSD11B1 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.